PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
January 5, 2004Science4,719 citations

In Vivo Activation of the p53 Pathway by Small-Molecule Antagonists of MDM2

View Full Paper
LVLyubomir T. VassilevBVBinh Thanh VuBGBradford Graves

Key Points

Key points are not available for this paper at this time.

Abstract

MDM2 binds the p53 tumor suppressor protein with high affinity and negatively modulates its transcriptional activity and stability. Overexpression of MDM2, found in many human tumors, effectively impairs p53 function. Inhibition of MDM2-p53 interaction can stabilize p53 and may offer a novel strategy for cancer therapy. Here, we identify potent and selective small-molecule antagonists of MDM2 and confirm their mode of action through the crystal structures of complexes. These compounds bind MDM2 in the p53-binding pocket and activate the p53 pathway in cancer cells, leading to cell cycle arrest, apoptosis, and growth inhibition of human tumor xenografts in nude mice.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Vassilev et al. (2004) studied this question.

synapsesocial.com/papers/69df2b143b0ba53fb37a1be3https://doi.org/10.1126/science.1092472
Ask AI
Helpful
Bookmark
Share
View Full Paper

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1p53 Mutations in Human Cancers1991 · 8,121 citations
  2. 2Retinoids: present role and future potential1999 · 220 citations
  3. 3A small synthetic peptide, which inhibits the p53-hdm2 interaction, stimulates the p53 pathway in tumour cell lines 1 1Edited by A. R. Fersht2000 · 141 citations
  4. 4Inhibiting the p53–MDM2 interaction: an important target for cancer therapy2003 · 764 citations
  5. 5What the papers say: The p53‐mdm2 autoregulatory feedback loop: A paradigm for the regulation of growth control by p53?1993 · 205 citations